Perstorp Holding AB (Publ.)

Interim report, January-March 2016 Conference call April 28th, 2016





Disclaimer

- This document contains financial information regarding the businesses and assets of Perstorp Holding AB (publ) (the "Company") and its consolidated subsidiaries (the "Group"). Such financial information may not have been audited, reviewed or verified by any independent accounting firm. The inclusion of such financial information in this document or any related presentation should not be regarded as a representation or warranty by the Company, any of its respective affiliates, advisors or representatives or any other person as to the accuracy or completeness of such information's portrayal of the financial condition or results of operations by the Group.
- This document contains information, data and predictions about our markets and our competitive position. While we believe this data to be reliable, it has not been independently verified and, while we are not aware of any material misstatements therein, we make no representation or warranty as to the accuracy or completeness of such information. Additionally, industry publications and such reports generally state that the information contained therein has been obtained from sources believed to be reliable but that the accuracy and completeness of such information is not guaranteed and in some instances state that they do not assume liability for such information. In those cases where third-party data has not proved readily available, we have relied on internal analyses, as well as information obtained from sources such as our customers, suppliers, trade and business organizations connected with the markets in which we operate. We cannot assure you that any assumptions underlying these statements are accurate or correctly reflect the state and development of, or our position in, the industry. While we believe our internal company research is reliable and the market definitions are appropriate, neither such research nor these definitions have been verified by any independent source.
- Certain statements in this document are forward-looking. By their nature, forward-looking statements involve known and unknown risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. Forward-looking statements are not guarantees of future performance. These factors include, among others: our level of indebtedness and capital structure and the terms of the notes and our other financing arrangements; our strategy, outlook and growth prospects, including our operational and financial targets; the competitive markets faced by both ourselves and our customers; the economic outlook in general and, in particular, economic conditions in the markets of the United States, Europe and Asia, and the expected growth of our markets; our ability to borrow or raise capital; costs and regulations related to contamination or exposure impacts from our operations or products; our expansion plans, including our ongoing geographic expansion and expansion of our production capacity; our ability to develop, market and launch commercially viable products; the cyclical nature of some of the industries in which we operate; our ability to manage and pass on raw material and other input costs; currency fluctuations; loss of key customers or suppliers for certain of our products; changes to or enforcement of governmental and environmental regulations and health and safety requirements across the multiple jurisdictions in which we operate; downtime at our facilities; inability to control our joint ventures or other similar business arrangements; loss of key personnel; ongoing and future tax audits and potential changes in applicable tax regulations; inadequate protection of our intellectual property rights; and expenses and reputational damage resulting from litigation.
- These and other factors could adversely affect the outcome and financial effects of the plans and events described herein. Forward-looking statements contained in this document regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. New risks can emerge from time to time, and it is not possible for us to predict all such risks, nor can we assess the impact of all such risks on our business or the extent to which any risks, or combination of risks and other factors, may cause actual results to differ materially from those contained in any forward-looking statements. The cautionary statements set forth above should be considered in connection with any subsequent written or oral forward-looking statements that we or persons acting on our behalf may issue. Neither the Company nor the Group undertakes any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You should not place undue reliance on forward-looking statements, which speak only as of the date of this document.
- By attending this presentation, you are agreeing to be bound by the foregoing limitations.



Important notice

- Unless otherwise stated, the financial information presented in this document represents the Group's continuing operations, i.e. excluding:
 - 15% stake in Vencorex (the former Coating Additives business unit, 51% divested in May 2012 and 34% divested in August 2014)
- During the second quarter 2015, the Board of Directors decided to realign Perstorp's organizational structure as part of its transformation and started to report its financial performance based on the three reportable segments Specialties & Solutions, Advanced Chemicals & Derivatives and BioProducts. As a consequence of this, historical segment numbers have been adjusted accordingly for comparative purposes





Agenda

- Business performance
- Financial review
- Summary
- ➡ Q&A





Business performance



Jan Secher President & CEO

1000



Executive summary


- Organic volume-based sales growth was flat vs. a strong Q1 last year. Excluding BioProducts, organic volume-based sales growth was up 1.5%
- Solid growth for our specialty products proven by an all-time high sales record for Capa. The BioProduct business had somewhat lower volumes and some of our other product lines experienced a competitive market
- Q1 sales amounted to SEK 2,616 m, a 11% decrease over last year reflecting the decline in raw material prices. Sales increased 8% compared to Q4/15
- Marginal contribution as well as unit margins have remained stable on a healthy level despite lower sales prices for several products
- EBITDA excluding non-recurring items amounted to SEK 457 m in Q1/16 compared to SEK 531 m last year and SEK 238 m in Q4/15. The shortfall vs. Q1 last year was mainly due to unfavorable FX revaluation effects, amounting to SEK 65 m
- Q1 EBITDA margin amounted to 17,5% driven by a strong and solid performance in our specialty business
- ➡ Cash flow was on par with last year and amounted to SEK 319 m



Market overview

- Overall demand was stable in our major markets but general sales prices have declined as a consequence of lower raw material prices
- Sales in EMEA were 14% lower than the corresponding period last year primarily following generally lower sales prices but also lower volumes.
 Volumes were 5% below last year, mainly driven by less demand in the Fuel segment. Excluding BioProducts, volumes were 3% below last year






- Sales in Americas were 17% below Q1 last year mainly due to lower sales prices but also volumes were down 6% following a weak demand in South America and a continued depressed oil drilling market significantly affecting our Formates business
- Sales in APAC were 3% above Q1 last year following substantially higher volumes, +25% increase vs. last year, partly offset by lower sales prices mainly linked to BA Advanced Chemicals & Derivatives




Key net sales drivers during Q1

- ➡ Year-on-year growth was flat with a strong comparison quarter
 - Organic volume-based sales growth was flat year-on-year. Excluding Business Area BioProducts, organic volume-based sales growth amounted to +1.5%
- Average selling prices in SEK decreased year-on-year due to a decline in raw material prices
 - Reported SEK-prices in Q1/16 decreased 11% year-on-year mainly following the lower raw material prices and increased competition in some product lines
 - No FX-effects compared to Q1/15, a slightly weaker USD (Q1 avg rate) was offset by a stronger EUR





Raw materials and margins




- Key raw material prices decreased during the quarter
 - Average price for Brent crude oil decreased by 22% in Q1/16 vs Q4/15 and was close to 40% lower than in Q1/15
 - Propylene decreased 15% in Q1/16
 - Benzene decreased 3% in Q1/16
 - Methanol decreased 10% in Q1/16
- Year-on-year unit margins were stable helped by successful margin management, but offset by increased competition in some product lines. Continuous focus on pricing excellence in combination with lower raw material prices have enabled enhanced margins for some products
- Margins achieved in Q1/16 were significantly higher than Q4/15




Specialties & Solutions

- Stronger volumes in combination with stronger unit margins
 - Q1/16 net sales amounted to SEK 662 m, 6% higher than Q1/15, impacted by higher volumes, partly offset by lower sales prices. No FX-effects on net sales
 - Organic volume-based sales growth was 8%¹
 - Q1/16 EBITDA amounted to SEK 196 m, corresponding to an EBITDA margin of 30%. Earnings show an increase of 27% compared to Q1/15, impacted by a combination of stronger unit margins due to successful margin management and stronger volumes

¹= in Q1/16, one product line was transferred from Business Area Advanced Chemicals & Derivatives; adjusted for this, the organic volume-based sales growth was 4%.









Advanced Chemicals & Derivatives

- Earnings negatively affected by less favorable market conditions
 - Q1/16 net sales amounted to SEK 1,632 m, 17% lower than Q1/15 fully assignable to lower sales prices. No volume or FX-effects on net sales
 - Organic volume-based sales growth was flat vs. Q1/15
 - Q1/16 EBITDA amounted to SEK 266 m, corresponding to a EBITDA margin of 16%. Earnings decreased vs. Q1/15 mainly due to negative impact from less favorable market conditions on Oxo alcohols, Neo and Formates

¹= in Q1/16, one product line was transferred to Business Area Specialty & Solutions; adjusted for this, the organic volume-based sales growth was 1%







Net sales development



BioProducts

- Lower volumes due to less favorable market conditions
 - Q1/16 net sales amounted to SEK 270 m, 14% lower than Q1/15, impacted by lower sales volumes due to less favorable market conditions and slightly negative FX effects, partly offset by higher sales prices
 - Organic volume-based sales growth was -16%
 - Q1/16 EBITDA amounted to SEK 4 m compared to SEK 13 m in Q1/15. The decline in earnings can be assignable to lower volumes
 - The ramp up of the Norwegian plant progressed well with material on specification for the entire quarter








Valerox update


Overview

- ► The new production plant for Valeraldehyde and its derivatives 2-PH, Emoltene100TM and Valeric Acid, was successfully started early January 2015
- The 2nd Valerox-reactor was installed during the scheduled shutdown in September/October 2015 and increased capacity with 35kT of Valeraldehyde
- Marginal contribution in 2015 was negatively impacted by temporary use of sourced material instead of own material during Q1/2015, due to unscheduled (force majeure) lack of supply from our supplier and Q4/2015 due to scheduled maintenance shutdown
- Sold volumes have ramped up, especially for Emoltene[™]100
- We are confident we will achieve our targeted productivity and cost situation


Volumes and Marginal Contribution of Valerox related products



Valerox Q1 production capacity utilization







13 Source: Company information



Financial review



Magnus Heimburg CFO

1

15315

. .




Financial highlights Q1 2016

SEK m	Q1 -16	Q1 -15	LTM Q1-16	Q4 -15
Net Sales	2,616	2,949	10,816	2,431
% growth (y-o-y)	-11%			
Marginal Contribution	910	920	3,405	698
% of sales	34,8%	31,2%	31,5%	28,7%
EBITDA, reported	443	525	1,571	227
% of sales	16,9%	17,8%	14,5	9.3%
EBITDA, excl non recurring items	457	531	1,593	238
% of sales	17,5%	18,0%	14,7%	9.8%

- Volume-based sales growth was flat, whereas Net sales decreased around 11% compared to Q1/15, mainly as a consequence of declining raw material prices
- Marginal contribution was close to the same level as last year. Unit margins (SEK/kg) were stable year-on-year whereas margins in % of sales improved to c. 35%
- EBITDA excluding non recurring items amounted to SEK 457 m vs. 531 m Q1/15, primarily affected by less favorable FX revaluation effects



Bridge EBITDA excl. non recurring items Q1 - 16 vs. Q1 - 15




Q1/16 EBITDA excluding non recurring items decreased SEK 75 m year-on-year, primarily explained by less favorable FX revaluation effects. Net effect from price/unit margin was slightly negative driven by margin pressure in some product lines, partly offset by somewhat positive product mix



LTM development Q1/13 to Q1/16

EBITDA excluding non recurring items




- ➡ Reported LTM EBITDA amount to SEK 1,593 m in Q1/16
- Adjusting for the negative effects from the shutdown in Q4/15, which will impact the LTM result until Q4/16, the LTM EBITDA would have been around SEK 1,720 m




Free cash flow

- Free cash flow in Q1/16 was SEK 319 m compared to 333 m in Q1/15
- The weaker EBITDA was to a large extent offset by a more favorable development of working capital and slightly lower investments
- Utilization of the trade receivable program amounted to €101 m per end of Q1/16, with credit approval amounting to €125 m
- Free cash flow in Q2/16 is expected to be positive





Working capital




- Reported working capital increased SEK 51 m during Q1/16 mainly due to a build-up of inventory
- Reported accounts receivable increased by SEK 75 m affected by higher sales primarily due to seasonality and no negative shutdown effects. The increase has been partly offset by lower sales prices and higher utilization of the trade receivable program
- Inventory value increased SEK 100 m during Q1/16 primarily due to higher volumes in preparation for upcoming normal scheduled maintenance shutdowns in Q2. Increased inventory volumes were partly offset by lower raw material prices
- The long term off-balance trade receivables financing program affect AR and working capital with around SEK 929 m (€ 101 m)

AP days is calculated as AP divided by most recent COGS excluding depreciation

Investments

- Investments amounted to SEK 99 m in Q1/16 and was slightly lower than in Q1/15
- Both maintenance investments as well as strategic investments were similar to the corresponding period last year
- Strategic investments includes the last part of the capacity expansion in Stenungsund as well as smaller debottlenecking investments in other platforms
- The total investment amount for 2016 estimated to be around SEK 600 m compared to SEK 660 m in 2015





Indebtedness

Current capital structure details

	USDm equiv.	SEKm	x EBITDA excl non-rec.
Cash on balance sheet	-86	-702	
Senior secured notes (€)	306	2,493	
Senior secured notes (\$)	380	3,096	
Net senior secured debt	600	4,887	3.1 x
Second lien notes (\$)	370	3,014	
Net second lien debt	970	7,901	5.0 x
Mezzanine loans (€)	422	3,443	
Other debt	5	38	
Net debt, excl. pensions and shareholder loan	1,397	11,382	7.1 x

Fx rates; USD 8.15 and Euro 9.23

Based on EBITDA excluding non-recurring items of SEK 1,593 m


- Net debt, excl. pensions and the shareholder loan increased by SEK 187 m during Q1/16, following capitalization of mezz PIK interest, slightly negative cash flow after financial net, partly offset by positive translation effects from FX rates
- Available funds per end of Q1/16 amounted to SEK 896 m (undrawn RCF and cash, excl. restricted)

Debt by currency

49% 51% = USD = EUR



Financial performance and leverage



Net debt excl SHL and pensions / EBITDA excl non recurring items — LTM EBITDA excl non recurring items



Summary



Jan Secher President & CEO

8

100100

2.2



Q1 conclusion and current trading

- Specialties & Solutions saw a clear improvement over last year, with healthy growth in some of our specialty areas
- Within Advanced Chemicals & Derivatives, our Penta and TMP businesses developed well. A few of our businesses – Neo, Formates and the alcohol product lines in our Oxo business faced headwind
- Solid marginal contribution generation and strong cash flow development
- EBITDA on par with last year's very strong level when excluding for FX revaluation effects
- We expect demand to continue to be stable for our main product lines in the second quarter of 2016 with a solid performance within our specialty businesses. In some product lines, as in Q1, we expect continued competitive market conditions mainly for our Oxo alcohols. We have a number of minor scheduled maintenance shutdowns during the second quarter
- Following the Company's continued robust performance, Perstorp, together with its shareholders, is assessing a range of strategic options, including a potential stock exchange listing or a refinancing of the capital structure



Q&A



Jan Secher President & CEO



Magnus Heimburg CFO





Appendix

Nutrition Facts:

Apples, raw, with skin Serving size 125g

Calories 65 Calories from fat 2

Calories IN % Daily Value 0%

Amount Per Serving

% Daily V: Total Fat 0g Saturated Fat 0g Trans Fat Cholesterol 0mg Sodium 1mg Total Carbohydrate 17g. 6 Dietary Fiber 3g Sugars 13g



Free cash flow details

Continuing operations (i.e. excluding Vencorex)

SEK m	Q1-16	Q1 -15	LTM Q1-16	Q4-15
EBITDA excl non-rec items	457	531	1,593	238
Change in working capital ¹	-39	-93	174	213
Maintenance capex	-39	-41	-316	-119
FCF before strategic capex	379	397	1,451	332
% of EBITDA excl non-rec.	83%	75%	91%	139%
Strategic capex	-60	-64	-338	-126
Free cash flow	319	333	1,113	206
% of EBITDA excl non-rec.	70%	63%	70%	87%

¹ = excluding exchange rate effects and provisions

Segment reporting

Continuing operations (i.e. excluding Vencorex)

SEK m	Q1-16	Q4-15	Q3-15	Q2-15	Q1-15	Q4-14	Q3-14	Q2-14	Q1-14
Net Sales	2,616	2,431	2,778	2,991	2,949	2,606	2,838	2,867	2,773
Specialties & Solutions	662	528	602	620	626	539	627	611	561
Advanced Chemicals & Derivatives	1,632	1,486	1,840	1,986	1,964	1,738	1,886	1,890	1,823
BioProducts	270	365	286	315	313	295	282	305	315
Other/eliminations	52	64	61	70	46	34	43	61	74
EBITDA, reported	443	227	420	481	525	291	385	317	276
Specialties & Solutions	196	85	142	143	154	78	118	118	87
Advanced Chemicals & Derivatives	266	133	317	314	377	215	252	205	227
BioProducts	4	-3	1	5	13	7	19	20	14
Other/eliminations	-22	12	-40	19	-19	-9	-4	-26	-52
EBITDA excl non recurring items	457	238	422	476	531	279	386	329	324
Specialties & Solutions	196	85	142	143	154	79	118	117	87
Advanced Chemicals & Derivatives	266	133	317	314	377	215	253	206	227
BioProducts	4	-3	1	5	13	7	19	20	14
Other/eliminations	-9	23	-38	14	-13	-22	-4	-14	-4



Quarter on quarter development

Continuing operations (i.e. excluding Vencorex)

SEK m	Q1-16	Q4-15	Q3-15	Q2-15	Q1-15	Q4-14	Q3-14	Q2-14	Q1 -14
Net Sales	2,616	2,431	2,778	2,991	2,949	2,606	2,838	2,867	2,773
Marginal Contribution	910	698	851	946	920	692	755	727	723
% of sales	34.8%	28.7%	30.6%	31.6%	31.2%	26.6%	26.6%	25.4%	26.1%
EBITDA, reported	443	227	420	481	525	291	385	317	276
% of sales	16.9%	9.3%	15.1%	16.1%	17.8%	11.2%	13.6%	11.1%	10.0%
EBITDA, excl non- recurring items	457	238	422	476	531	279	386	329	324
% of sales	17.5%	9.8%	15.2%	15.9%	18.0%	10.7%	13.6%	11.5%	11.7%



Cash and Available funds

SEK m	Q1-16	SEK m	Q1-16
Unrestricted cash	503	Unrestricted cash	503
Restricted ¹ and escrowed cash ²	199	RCF not Drawn	393
Cash on Balance Sheet	702	Reported Available Funds	896

¹⁾ Cash in Perstorp accounts in countries where international movement of funds are restricted.
²⁾ Cash held in escrowed accounts as collateral for different business activities (including Vencorex)



Currency

Period average exchange rates

SEK per LOC	Q1 -16	Q1 -15	LTM Q1 -16	Q4 -15
USD	8.46	8.34	8.46	8.50
Euro	9.32	9.38	9.34	9.31
GBP	12.10	12.62	12.77	12.91

Period end exchange rates

SEK per LOC	Q1 -16	Q1 -15	Q4 -15
USD	8.15	8.62	8.35
Euro	9.23	9.29	9.14
GBP	11.69	12.74	12.38


Source: Swedish Central Bank, Riksbanken





Currency

Q1 2016





Q1 -16	Q1 -15	Q4 -15
8.46	8.34	8.50
9.32	9.38	9.31
12.10	12.62	12.91
	8.46 9.32	8.46 8.34 9.32 9.38

End rate SEK per LOC	Q1 -16	Q1 -15	Q4 -15
USD	8.15	8.62	8.35
Euro	9.23	9.29	9.14
GBP	11.69	12.74	12.38

